German, French and Italian: Language Compliance for Product Information

This article is number 10 in Volume 1, Regulatory Framework and Fundamentals, of the fifty-part series on medical device registration in Switzerland. Together with the other nine articles in this volume it forms a complete deliverable on this topic. The publication timestamp, article number, article title and unique URL are listed in the table below.

1. Key takeaways

Three languages are the default; fewer languages are the exception that must be proven. MedDO Art. 16(2) requires product information (labels and instructions for use) to be written in the three official Swiss languages, with only symbols established by technical standards able to replace text; Art. 16(3) permits a reduction of languages or the use of English only when four conditions are met simultaneously; Art. 16(7) prohibits misleading or contradictory information. The correct way to compress language cost is to exhaust symbol substitution and layout consolidation first, and only then to assess whether the evidence for reducing languages actually holds. Companies that reverse this order usually end up redoing both, because a rejected language reduction forces late reprinting at full trilingual volume.

2. Legal basis

Verification entry points: MedDO Article 16, paragraphs 2, 3 and 7, covering the three official languages and the four conditions for reducing the number of languages. Because the language scheme interacts with the conformity mark under Art. 13, the placement rules under Art. 14 and the advertising rules under Art. 69(2), the verification should cover all cited provisions together rather than Art. 16 in isolation.

3. Expert insights

1. The trilingual mandate of Art. 16(2) and the symbol exception. Product information must be written in the three official languages German, French and Italian, and symbols established by technical standards may replace text. Conclusion: symbol substitution is the most effective way to reduce language cost, because it directly cuts the volume of text that must be translated and depends on no conditions. It can be implemented immediately, before any legal analysis of the exception route is even started.

The trade-off: reliance on symbols needs to be coordinated with the instructions for use, and over-symbolisation weakens the readability of warnings and precautions; the test is whether users can obtain complete information from the combination of symbols and the remaining text.

2. The four conditions of Art. 16(3) are joined by and, not by or. Supply only to professional users, or custom-made or in-house devices; users having the necessary professional and language competence and consenting; protection of patients, users and third parties remaining assured; and effectiveness and intended use not being impaired. Conclusion: if written evidence cannot be produced for even one condition, neither language reduction nor English use stands. The counterpoint: treating use by professionals only as the sole threshold, while ignoring the arguments on user consent and the level of protection, is the most frequent reason why language reduction schemes are rejected.
3. Art. 16(7) turns multilingual risk from a cost issue into a compliance issue. The provision prohibits misleading or contradictory information on intended use, safety and performance, and echoes the prohibition of misleading advertising in Art. 69(2). Conclusion: the real risk of multiple language versions is inconsistency between the translations; once one language version states a warning more weakly than the others, it may constitute contradictory information. Reviewing only one language version while leaving the others to machine translation concentrates the risk in the weakest version.

4. Practical recommendations

1. Finalise the language scheme before conformity assessment starts, so that instructions for use and labels do not have to be redone later.
2. Give priority to replacing text with symbols established by technical standards, record the standards relied upon, and build a symbol-to-text mapping table.
3. Where languages are to be reduced or English used, document the evidence for each of the four Art. 16(3) conditions in writing and obtain the written consent of users.
4. Perform a cross-version consistency review of the three language versions, maintaining a language comparison and version record, with warnings and precautions checked first.
5. For IVD products, check the product information requirements of IvDO Art. 15(1) in parallel; do not apply the device template unchanged.
6. Determine label placement by the order of Art. 14 (device body or sterile packaging, then packaging, then instructions for use and sales packaging), and lay it out together with the language scheme.

5. Verification checklist

• □ Labels and instructions for use are provided in German, French and Italian (Art. 16(2))
• □ Symbols used map to established technical standards, with the mapping table retained
• □ Any language reduction or English scheme has written evidence of the four Art. 16(3) conditions and user consent
• □ The three language versions have passed a cross-version consistency review with no contradictory statements (Art. 16(7))
• □ IVD products have been checked against IvDO Art. 15(1) in parallel
• □ Conformity mark placement and language layout have been reviewed against Art. 13 and Art. 14

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers and economic operators entering the Swiss market with end-to-end Swissmedic registration and compliance services, including trilingual labelling and instructions for use schemes under MedDO Art. 16, Art. 16(3) condition documentation, symbol substitution strategies, cross-version consistency reviews, and IvDO Art. 15(1) alignment for IVD product information. For tailored guidance on your product portfolio, contact info@grzanglobal.com.